ArticleAnalytical chemistry2026
His-Tag-Aptamer-Liposome-Conjugates as a Multipurpose Tool for Recombinant Protein Screening and Protein-Based Bioassays.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposome-aptamer conjugates are powerful tools for bioanalysis and drug delivery by taking advantage of aptamer binding specificity and liposome encapsulation capabilities. Here, we developed multipurpose conjugates that specifically and effectively bind to his-tags and demonstrated their capability as screening tool for his-tagged proteins and as signaling tool for bioassays. Using the poly histidine-tag (his-tag) binding aptamer NDM1-H14-01 (his-Apt), we studied aptamer-liposome immobilization with special focus on retaining aptamer functionality and liposome integrity. This involved various strategies for modifying liposomes with aptamers, i.e., cholesterol-functionalized aptamers were inserted into the liposome pre- or post-synthesis, amine-modified aptamers were covalently coupled to COOH-groups on the liposome surface, and biotinylated aptamers were incubated with streptavidin-modified liposomes, respectively. Extensive characterization of liposome and aptamer properties, as well as conjugate functionality via heterogeneous binding assays, proved post-insertion and biotinylated aptamers successful with a stability of at least 4 months at 4 °C, whereas the other methods destabilized the aptamer structure. The successful conjugates were further optimized to (i) serve as a tool for easy detection and screening of his-tag accessibility in recombinant proteins, which can replace common metal-based formats (ii) enable efficient site-directed immobilization of proteins onto liposomes while omitting the need of additional protein modifications, and (iii) demonstrate that aptamers can function as a reliable secondary recognition element for protein-modified liposomes, e.g., as internal control system. Consequently, these highly functional and stable his-Apt-liposome conjugates represent a versatile platform technology for bioassays, which can substitute labor- and cost-intensive measurements, as well as improve assay control and reproducibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.